Chapters

Transcript

Video

If the rationale for upstream decoupling of the androgen and cortisol pathways at the level of CRF inhibition is confirmed, what are the potential advantages in terms of reducing glucocorticoid dose?

If the rationale for upstream decoupling of the androgen and cortisol pathways at the level of CRF inhibition is confirmed, what are the potential advantages in terms of reducing glucocorticoid dose?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Ellen Seely, MD

Ellen Seely, MD

Vice Chair, Faculty Development
Department of Medicine
Director of Clinical Research, Endocrinology, Diabetes and Hypertension Division
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA